This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Calendar: Key Dates for May

Stocks in this article: DNDN AVNR CBRX MNKD VRTX NPSP OPTR

Updated with information on Biomimetic Therapeutics.

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for May:

April 30-May 4:
American College of Obstetrics and Gynecologists (ACOG) annual meeting. Investor focus will be on Columbia Labs (CBRX - Get Report) and KV Pharmaceutical (KV-A).

May 2:
Dendreon (DNDN) first-quarter earnings.

May 3:
Vertex Pharmaceuticals (VRTX - Get Report) first-quarter earnings.
Mannkind (MNKD) presents at the Deutsche Bank healthcare investor conference.
Alimera Sciences (ALIM) presents new Iluvien diabetic macular degeneration data at Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

May 4:
Mannkind meets with FDA regarding Afrezza.

May 7:
Estimated FDA approval decision date for Merck's (MRK) hepatitis C drug boceprevir.

May 7-10:
Digestive Disease Week research meeting, including data presentation from NPS Pharmaceuticals (NPSP - Get Report) and Ironwood Pharmaceuticals (IRWD).

May 9:
Avanir Pharmaceuticals (AVNR) first-quarter earnings.
Mannkind first-quarter earnings.

May 12:
FDA advisory panel convenes to review Biomimetic Therapeutics' (BMTI) Augment Bone Graft.
Lexicon Pharmaceuticals (LXRX) analyst/investor meeting.

May 18:
American Society of Clinical Oncology (ASCO) releases research abstracts for its annual meeting in June.

May 19:
FDA convenes advisory panel to review cardiovascular safety of Abbott Labs' (ABT) lipid-lowering drug Trilipix.

May 23:
FDA approval decision date for Vertex's hepatitis C drug telaprevir.
FDA approval decision date for Johnson & Johnson's (JNJ) HIV drug rilpivirine.

May 25-28:
European League Against Rheumatism (EULAR) annual meeting.

May 26:
Johnson & Johnson analyst/investors meeting.
Xoma (XOMA) shareholder meeting.

May 30:
FDA approval decision date for Optimer Pharmaceuticals' (OPTR) antibiotic fidaxomicin.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,293.48 -93.73 -0.54%
S&P 500 2,018.48 -11.07 -0.55%
NASDAQ 4,675.21 -6.2870 -0.13%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs